StockStory.org on MSN
DXCM Q1 deep dive: US growth moderates as product momentum and coverage expansion drive strategy
Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results , with sales up 15% year on year to $1.19 billion. The ...
DexCom (NASDAQ: DXCM) held its first-quarter earnings conference call on Thursday. Below is the complete transcript from the ...
I’ve contributed to PCMag since 2019, covering all kinds of consumer electronics. As a self-identifying early adopter of technology, I’ve stumbled through the changing devices over the years and ...
In December, online rumors hinted at the fact that Dexcom may be planning to sunset its G6 CGM sensor model. The company has now started to notify patients of the discontinuation plan. The company ...
Feb 12 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab beat Wall Street estimates for fourth-quarter results on Thursday, driven by robust demand for its continuous glucose monitoring ...
DexCom, which has underperformed its medical equipment and S&P 500 peers in a big way in 2025, could be staring at better prospects next year. Stelo is facing vast and underpenetrated prediabetes and ...
Dexcom Smart Basal is designed to make basal insulin initiation and management simpler and more personalized for users and their healthcare providers. * Dexcom Smart Basal is FDA cleared and now the ...
DexCom (DXCM) stock ought to be included on your watchlist. Here is why – it is presently trading within the support range ($55.31 – $61.13), levels from which it has bounced significantly in the past ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. People with Type 1 diabetes are estimated to make up to 180 more ...
This combined sensor-transmitter continuous glucose monitor (CGM) technology offers glucose values every 5 minutes. Sensors last for up to 10-15 days and provide alerts for high and low blood sugars ...
DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...
Hunterbrook Media released a short report on diabetes-focused DexCom Inc. (NASDAQ:DXCM), citing that the company sold the "adulterated" device. Benzinga reached out to DexCom for comments and is yet ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results